# Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

> **NCT06139575** · PHASE1,PHASE2 · RECRUITING · sponsor: **Bivision Pharmaceuticals, Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Lutetium Lu 177 JH020002 Injection

## Key facts

- **NCT ID:** NCT06139575
- **Lead sponsor:** Bivision Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-22
- **Primary completion:** 2026-05
- **Final completion:** 2027-07
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06139575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06139575, "Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06139575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*